Herve Ghesquieres
Overview
Explore the profile of Herve Ghesquieres including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
190
Citations
3299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Camus V, Molina T, Desmots F, Blanc-Durand P, Kanoun S, Moslemi A, et al.
Blood Adv
. 2025 Mar;
PMID: 40030008
The GAINED study (NCT01659099) was a randomized phase 3 trial comparing obinutuzumab (G) to rituximab (R) plus ACVBP or CHOP14 induction, followed by PET-guided consolidation. This post-hoc analysis aimed to...
2.
Kwiatek M, Guru Murthy G, Hoffmann M, Tessoulin B, Danilov A, Alencar A, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 40000354
Background: LOXO-338 is a novel, orally bioavailable small-molecule inhibitor of Bcl-2, designed to achieve selectivity for Bcl-2 over Bcl-xL, thus avoiding dose-limiting thrombocytopenia associated with Bcl-xL inhibition. This first-in-human, open-label,...
3.
Marouf A, Chaubard S, Lievin R, Michot J, Molinari N, Rossignol J, et al.
Hemasphere
. 2025 Jan;
9(1):e70081.
PMID: 39840381
No abstract available.
4.
Bartlett N, Hahn U, Kim W, Fleury I, Laribi K, Bergua J, et al.
J Clin Oncol
. 2025 Jan;
43(9):1061-1072.
PMID: 39772655
Purpose: In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy...
5.
Sureda A, Pinto A, Ghesquieres H, Morschhauser F, Tournilhac O, Mutsaers P, et al.
Hematol Oncol
. 2024 Dec;
43(1):e70000.
PMID: 39617826
A significant unmet need remains for patients with Hodgkin lymphoma (HL) who fail to respond to first-line treatment or experience an early relapse. Tinostamustine, a novel alkylating deacetylase inhibitor, inhibits...
6.
Mainguy A, Soussain C, Touitou V, Bennedjai A, Kodjikian L, Ghesquieres H, et al.
Bone Marrow Transplant
. 2024 Nov;
60(3):297-304.
PMID: 39562715
Despite its indolent evolution, vitreoretinal lymphoma (VRL) has a poor prognosis due to a major risk of relapse in the central nervous system (CNS) and may necessitate aggressive therapy. However,...
7.
Abramson J, Ku M, Hertzberg M, Huang H, Fox C, Zhang H, et al.
Lancet
. 2024 Nov;
404(10466):1940-1954.
PMID: 39550172
Background: Glofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a...
8.
Sesques P, Karlin L, Massy E, Maarek A, Aussedat G, Lazareth A, et al.
Front Oncol
. 2024 Nov;
14:1436587.
PMID: 39544298
Background: In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus...
9.
Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M, et al.
Eur J Cancer
. 2024 Nov;
213():115073.
PMID: 39509848
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements...
10.
Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, et al.
J Hematol Oncol
. 2024 Oct;
17(1):102.
PMID: 39468591
Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After...